TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Roth Capital Reaffirms TG Therapeutics (TGTX) at 'Buy'; Still Sees TGR-1202, TG-1101 as Well Positioned
November 7, 2016 2:51 PM ESTRoth Capital affirms TG Therapeutics (Nasdaq: TGTX) with a Buy/Focus Pick rating and $33 price target following Q3 results and update issued earlier Monday.
Analyst Joseph Pantginis commented today: We believe that the company is well positioned with two of its candidates, TGR-1202 and TG-1101, moving through multiple clinical trials for multiple... More
TG Therapeutics (TGTX) Misses Q3 EPS by 19c
November 7, 2016 7:34 AM ESTTG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.50), $0.19 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $30 thousand.
Cash, cash equivalents, investment securities, and interest receivable were $60.7 million as of September 30, 2016.
For... More
